▶ 調査レポート

生物兵器防衛の世界市場:製品別、地域別分析

• 英文タイトル:Global Biodefense Market - Segmented by Product and Geography - Growth, Trends, and Forecast (2018 - 2023)

が調査・発行した産業分析レポートです。生物兵器防衛の世界市場:製品別、地域別分析 / Global Biodefense Market - Segmented by Product and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-06002資料のイメージです。• レポートコード:B-MOR-06002
• 出版社/出版日: / 2018年6月20日
• レポート形態:英文、PDF、107ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User(1名様用)¥454,750 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥481,500 (USD4,500)▷ お問い合わせ
  Corporate User¥936,250 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、生物兵器防衛の世界市場について調べ、生物兵器防衛の世界規模、市場動向、市場環境、製品別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・生物兵器防衛の世界市場インサイト
・生物兵器防衛の世界市場環境
・生物兵器防衛の世界市場動向
・生物兵器防衛の世界市場規模
・生物兵器防衛の世界市場規模:製品別
・生物兵器防衛の世界市場:地域別市場規模・分析
・生物兵器防衛の北米市場規模・予測
・生物兵器防衛のアメリカ市場規模・予測
・生物兵器防衛のヨーロッパ市場規模・予測
・生物兵器防衛のアジア市場規模・予測
・関連企業情報・競争状況

The global biodefense market is expected to register a CAGR of 6.5% during the forecast period, 2018 to 2023. Bioterrorism is the use of biological agents that are harmful for mankind. Biodefense includes medical measures to protect from biological agents. Key factors driving the market growth are rise in technological advancement, such as nanotechnology, database management systems, advanced detector hardware, and gene chips for pathogen detection in the forensic department. Also, the rise in the production of vaccines, enhanced forensics, and quick diagnostic procedures and detection techniques are the factors expected to drive the market growth. Additionally, due to the recent outbreak of Nipah, Ebola, and Zika viruses governments are increasing R&D funding. Increasing investments by regional governments of developed countries for biodefense are also expected to enhance the market growth over the forecast period.

Favorable Government Initiatives
Governments spend huge sums of money every year for the R&D of vaccines in order stay prepared for any bioterrorism attacks. Pharmaceutical companies operating in the biodefense sector have huge opportunities to expand due to governments’ drive to be prepare for any kind of bioterrorism. For instance, in 2004, the US congress passed the Project Bioshield act, calling for USD 5 billion investment for purchasing vaccines which can be used in the event of a bioterrorist attack. This act was designed to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents for civilian use. Such government initiatives are expected to propel the growth of the biodefense market.
Other factors driving this market are rapid technological advancements and increasing investments by regional governments in developed countries.

Low Market Penetration in Developing and Underdeveloped Countries
The growth of biodefense market may be hampered by the low market penetration in the developing and underdeveloped countries. Limited government interventions and funding for biodefense materials are some of the major reasons restraining the growth of the market. Developed countries have more resources to be prepared for a bio war when compared to developing countries.

North America to Dominate the Market
North America dominated the global biodefense market in 2017, which can be attributed to the increase in government funding to generate and stockpile sufficient vaccines to be used against anthrax through various initiative, such as BioShield act, Biomedical Advanced Research and Development Authority (BARDA), and Joint Program Executive Office for Chemical & Biological Defense. For instance, the US Department of Health and Human Services announced it plans to spend more than USD 25 million on an anthrax antitoxin, as a part of an emergency preparedness plan in 2018. In May 2018, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that USD 25 million was granted to advance the development and manufacture of a vaccine against the Nipah virus (NiV) to major market players, like Profectus BioSciences Inc. and Emergent BioSolutions Inc. The above mentioned initiatives by government are expected to boost the growth of the market in the region.

Key Developments in the Market
• February 2018 – Bavarian Nordic A/S announced positive results from a Phase 3 pivotal study of its investigational and non-replicating smallpox vaccine, IMVAMUNE
• March 2017 – PharmAthene Inc. a biodefense company developing medical countermeasures against anthrax, announced that it has established a record date and meeting date for a special meeting of stockholders to vote upon, among other things, the proposal to adopt the agreement and plan of merger and reorganization involving PharmAthene and Altimmune Inc.

Major Players: ALNYLAM PHARMACEUTICALS INC., BAVARIAN NORDIC, CLEVELAND BIOLABS, DYNPORT VACCINE COMPANY LLC, ELUSYS THERAPEUTICS INC., EMERGENT BIOSOLUTIONS INC., ICHOR MEDICAL SYSTEMS, OLOGY BIOSCIENCE, PHARMATHENE INC., AND SIGA TECHNOLOGIES INDUSTRIES LTD, amongst others.

Reasons to Purchase this Report
• Current and future global biodefense market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Pipeline Analysis
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Consumers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitute Product and Services
5.3.5 Competitive Rivalry within the Industry
5.4 Regulatory Scenario
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Favorable Government Initiatives
6.1.2 Increasing Investments by the Regional Governments in the Developed Countries
6.1.3 Rapid Technological Advancements
6.2 Market Restraints
6.2.1 Low Market Penetration in Developing and Underdeveloped Countries
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Product
7.1.1 Anthrax
7.1.2 Botulism
7.1.3 Smallpox
7.1.4 Nuclear
7.1.5 Others
7.2 By Geography
7.2.1 North America
7.2.1.1 United States
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 France
7.2.2.2 Germany
7.2.2.3 United Kingdom
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Rest Of Europe
7.2.3 Asia-Pacific
7.2.3.1 China
7.2.3.2 Japan
7.2.3.3 India
7.2.3.4 Australia & New Zealand
7.2.3.5 South Korea
7.2.3.6 Rest of Asia-Pacific
7.2.4 Middle East & Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of the Middle East & Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Alnylam Pharmaceuticals Inc.
9.2 Bavarian Nordic
9.3 Cleveland BioLabs
9.4 DynPort Vaccine Company LLC
9.5 Elusys Therapeutics Inc.
9.6 Emergent BioSolutions Inc.
9.7 Ichor Medical Systems
9.8 Ology Bioscience
9.9 PharmAthene Inc.
9.10 SIGA Technologies
*List Not Exhaustive
10. Future of the Market